MGF IGF-1 EC

IGF-1Ec is encoded by the IGF1 gene (chromosome 12q23.2) through alternative splicing: exons 3–4 encode the mature IGF-1 domain (70 AA), an extra 49-nucleotide insert at the junction of exons 4 and 5 shifts the reading frame of exon 5, and exon 6 encodes the resulting unique 24-AA Ec E-peptide C-terminus. This produces a full-length precursor of approximately 105–110 amino acids (including signal peptide) before proteolytic processing. First characterised in mechanically loaded rabbit tibialis anterior by Goldspink et al. (J Physiol 1996; 495:469–73). In humans the same splice event was confirmed by Yang et al. (2003) and the growth plate expression was systematically documented by Schlegel et al. (PLoS One 2013, PMID 24146828). The endogenous full-length pro-IGF-1Ec is expressed in skeletal muscle, cardiac muscle, growth plate cartilage, brain, intestinal smooth muscle, prostate, and tendon in response to mechanical loading, hypoxia, or cytokine signalling (TGF-β1 in Crohn's disease, PMID 26428636). Commercial synthetic peptides sold as 'MGF' represent only the isolated 24-AA Ec E-peptide C-terminal fragment; the full-length IGF-1Ec precursor is a distinct, larger recombinant or synthetic construct. Synthetic full-length IGF-1Ec is produced by solid-phase peptide synthesis or recombinant E. coli/CHO expression for in vitro research. No regulatory approval in any jurisdiction for human therapeutic use.

The full-length IGF-1Ec precursor operates through two mechanistically coupled arms. (1) IGF-1 receptor (IGF-1R) axis: the N-terminal mature IGF-1 domain binds IGF-1R with similar affinity to IGF-1Ea, activating the PI3K/Akt and MAPK/ERK1-2 cascades to drive protein synthesis, cell survival, and myoblast differentiation. In the Yi et al. (2017) C2C12 study (PMID 28471324), full-length IGF-1Ec induced greater myogenic differentiation than either isolated mature IGF-1 or isolated E-peptide alone, and its proliferative effects were partially but not completely abolished by the IGF-1R inhibitor PQ401 at 50–100 ng/mL, indicating partial IGF-1R dependence with an additional receptor pathway. (2) Ec E-peptide / ERK5-MEF2C axis: the C-terminal 24-AA Ec domain engages a non-IGF-1R mechanism — demonstrated in Li et al. (2015, PMID 26428636) intestinal smooth muscle — activating ERK5 phosphorylation and nuclear translocation of MEF2C (myocyte enhancer factor 2C), driving smooth muscle protein accumulation (α-SMA, γ-SMA, smoothelin) and hypertrophy without cell proliferation. This ERK5/MEF2C pathway is insensitive to IGF-1R blockade. (3) Bioavailability tethering: the Ec E-peptide is highly basic (net charge ~+8 at physiological pH), enabling the full-length pro-IGF-1Ec to bind heparan sulphate proteoglycans in the extracellular matrix, confining signalling to the tissue of origin and preventing systemic IGF-1 elevation — a key safety distinction from exogenous systemic IGF-1 (Hede et al. 2012, PMID 23251442). (4) Proteolytic processing: proprotein convertases (furin, PACE4) cleave at the Lys-X-X-Lys-Arg71 pentabasic motif to release mature IGF-1 and free E-peptide; the full-length uncleaved form is thought to predominate in skeletal muscle cytoplasm and possibly in the nucleus (nuclear localisation signal RRRK within the Ec domain, PMID 24146828). (5) Temporal expression: IGF-1Ec mRNA is the first IGF-1 splice variant to increase after muscle damage, peaking at 24 h post-injury and preceding IGF-1Ea, correlating with Myf5 expression (satellite cell activation marker), then declining as IGF-1Ea rises to sustain differentiation (McKay et al. 2008, PMID 18818249). In older muscle, cumulative MGF expression across sequential exercise bouts is greater than in young muscle (Roberts et al. 2010, PMID 20668872), suggesting age-related impairment in efficient E-peptide processing or receptor sensitivity.

Preclinical outcomes studied with full-length IGF-1Ec or the isolated Ec E-peptide: (1) Satellite cell proliferation and fusion — MGF E-peptide (from IGF-1Ec) significantly increased progenitor cell numbers in healthy, dystrophic (DMD), and ALS human primary muscle cultures; increased fusion potential at multiple ages (Kandalla et al. 2011, PMID 21354439; Ates et al. 2007, PMID 17531227). (2) Myogenic differentiation — full-length IGF-1Ec induced strongest differentiation response vs isolated E-peptide or mature IGF-1 in C2C12 cells at 50 ng/mL (Yi et al. 2017, PMID 28471324). (3) Cell migration — IGF-1Ec increased C2C12 migration by ~49% vs ~18% for mature IGF-1, partially via non-IGF-1R pathways. (4) Neuroprotection in ALS — plasmid-delivered MGF (IGF-1Ec) produced greater motoneuron survival and hindlimb strength than IGF-1 in SOD1(G93A) mice (Riddoch-Contreras et al. 2009, PMID 19038252). (5) Smooth muscle hypertrophy — IGF-IEc/MGF drives ERK5/MEF2C-dependent intestinal smooth muscle hypertrophy in Crohn's disease fibrostenosis (Li et al. 2015, PMID 26428636). (6) Growth plate — IGF-1Ec represents ~33% of total IGF-1 expression across all growth plate zones in resting, proliferative, and hypertrophic chondrocytes, with cytoplasmic and nuclear localisation (Schlegel et al. 2013, PMID 24146828). (7) Cardiac protection — MGF E-domain peptide delivered via polymeric hydrogel microrods post-myocardial infarction decreased mortality, improved haemodynamics, and inhibited pathological hypertrophy in mouse MI model (Pena et al. 2015, PMID 25678113). (8) Inflammatory suppression — IGF-1Ec E-peptide reduced TNF-α, IL-1β, IFN-γ, TGF-β, and oxidative stress markers in stressed muscle preparations. (9) Satellite cell senescence delay — MGF E-peptide extended proliferative lifespan of muscle progenitors by approximately 14% in aging models. (10) Negative finding — Fornaro et al. (2014) found synthetic 24-AA Ec E-peptide had no effect on C2C12 myoblasts or primary human skeletal muscle stem cells at concentrations up to 500 ng/mL, challenging E-peptide-only studies (AJP Endo 2014); Rotwein's 2014 editorial further questioned whether endogenous E-peptide cleavage produces sufficient free peptide for autonomous signalling.